Prostate MRI and Ultrasound With Pathology and Coordinates of Tracked Biopsy (Prostate-MRI-US-Biopsy)

This dataset was derived from tracked biopsy sessions using the Artemis biopsy system, many of which included image fusion with MRI targets. Patients received a 3D transrectal ultrasound scan, after which nonrigid registration (e.g. “fusion”) was performed between real-time ultrasound and preoperative MRI, enabling biopsy cores to be sampled from MR regions of interest. Most cases also included sampling of systematic biopsy cores using a 12-core digital template. The Artemis system tracked targeted and systematic core locations using encoder kinematics of a mechanical arm, and recorded locations relative to the Ultrasound scan. MRI biopsy coordinates were also recorded for most cases. MRI targets were defined using multiparametric MRI, e.g. t2-weighted, diffusion-weighted, and perfusion-weighted sequences, and scored on a Likert-like scale with close correspondence to PIRADS version 2. t2-weighted MRI was used to trace ROI contours, and is the only sequence provided in this dataset. MR imaging was performed on a 3 Tesla Trio, Verio or Skyra scanner (Siemens, Erlangen, Germany). A transabdominal phased array was used in all cases, and an endorectal coil was used in a subset of cases. The majority of pulse sequences are 3D T2:SPC, with TR/TE 2200/203, Matrix/FOV 256 × 205/14 × 14 cm, and 1.5mm slice spacing. Some cases were instead 3D T2:TSE with TR/TE 3800–5040/101, and a small minority were imported from other institutions (various T2 protocols.) Ultrasound scans were performed with Hitachi Hi-Vision 5500 7.5 MHz or the Noblus C41V 2-10 MHz end-fire probe. 3D scans were acquired by rotation of the end-fire probe 200 degrees about its axis, and interpolating to resample the volume with isotropic resolution. Patients with suspicion of prostate cancer due to elevated PSA and/or suspicious imaging findings were consecutively accrued. Any consented patient who underwent or had planned to receive a routine, standard-of-care prostate biopsy at the UCLA Clark Urology Center was included.

本数据集源自采用Artemis活检系统开展的追踪式活检会话，其中多数集成了MRI靶点图像融合流程。患者首先接受3D经直肠超声扫描，随后对实时超声图像与术前MRI进行非刚性配准（即俗称“融合”），从而可从MRI感兴趣区（Region of Interest, ROI）中采集活检针芯样本。多数病例还通过12针数字模板完成系统活检针芯采样。Artemis活检系统借助机械臂的编码器运动学数据，追踪靶向活检与系统活检的针芯位置，并记录相对于超声扫描的空间坐标；多数病例同时记录了MRI活检靶点的坐标信息。MRI靶点通过多参数MRI定义，涵盖T2加权、弥散加权及灌注加权序列，并采用与前列腺影像报告和数据系统（Prostate Imaging Reporting and Data System, PIRADS）版本2高度契合的李克特式量表进行评分。本数据集仅提供用于勾勒ROI轮廓的T2加权MRI序列。MRI扫描采用3特斯拉Trio、Verio或Skyra扫描仪（西门子股份公司，德国埃尔兰根）。所有病例均使用经腹相控阵探头，部分病例额外配备直肠内线圈。多数脉冲序列为3D T2:SPC，其重复时间/回波时间（TR/TE）参数为2200/203，矩阵/视野为256×205/14×14 cm，层间距为1.5mm；部分病例采用3D T2:TSE序列，TR/TE参数为3800–5040/101；另有极少数病例的数据来自其他机构，采用各类T2扫描协议。超声扫描采用Hitachi Hi-Vision 5500 7.5 MHz设备或Noblus C41V 2-10 MHz端射探头完成。3D扫描通过将端射探头沿自身轴线旋转200度采集数据，并通过插值重采样为各向同性分辨率的体积数据。本研究连续入组因前列腺特异性抗原（Prostate Specific Antigen, PSA）升高和/或影像学表现可疑而疑似前列腺癌的患者；所有在UCLA克拉克泌尿外科中心接受或计划接受标准诊疗流程前列腺活检的知情同意患者均被纳入本数据集。